BioSpace News Archive

New research in the January 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that immunotherapy from immune checkpoint inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high colorectal cancer.

Mountain Valley MD Holdings Inc. announced that Dr. Azhar Rana, the Company’s Chief Medical Officer, will be transitioning to an advisory capacity effective February 1, 2023.

Landos Biopharma, Inc. today announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization domain.

Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, Cynthia Sirard, MD, Chief Medical Officer, and Jason Baum, PhD., Vice President and Head of Translational Medicine will present a corporate overview at B. Riley Securities’ 3rd Annual Oncology Conference.

KemPharm, Inc. announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer.

Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.

Celularity Inc. and CH Trading Group LLC announced that they have entered into an exclusive territory distribution agreement.

Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions.

Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on January 18 -19, 2023.

Aprea Therapeutics, Inc. today announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations.